NCT05405543

A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants

A Phase 1 Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of MYK-224 in Healthy Adult Japanese Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the effects of both single and multiple dose drug levels of MYK-224 in healthy adult Japanese participants.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	MYK-224	Specified dose on specified days
OTHER	Placebo	Specified dose on specified days

Timeline

• Start date: 2022-07-12
• Primary completion: 2022-11-16
• Completion: 2022-12-09
• First posted: 2022-06-06
• Last updated: 2023-01-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study